Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS

Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results

a record 39 SRT systems during the quarter; revenues of $13.1 million

fifth consecutive quarter of profitability; diluted EPS of $0.09

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (February 5, 2025) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly

effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions,

announces financial results for the three and 12 months ended December 31, 2024.

include the following:

"Our fourth quarter performance capped

an outstanding year with key metrics reflecting the growing adoption of our SRT systems. We are proud to have achieved record-high

quarterly unit shipments, along with continued profitability," said Joe Sardano, Chairman and Chief Executive Officer of

Sensus Healthcare. "Our Fair Deal Agreement program serves new customers who are seeking clinical value and financial flexibility.

Our primary focus is on securing exclusive agreements with corporate accounts, and then supporting a targeted, high-impact rollout

utilizing our data, resources and unmatched experience. We have had great success with this program since its launch a year ago,

and expect it to begin contributing to revenues in the second half of 2025.

"The sale of an SRT system to the

Pompano Veterinary Clinic demonstrates the versatility of our technology and its potential to address needs in companion animal

health," he added. "Additionally, we're making strategic progress on product innovation to expand our portfolio

and market opportunities, with plans to re-submit our TDI 510(k) application in the first half of 2025. Throughout the year we

will remain focused on driving growth and profitability by expanding patient access to non-invasive treatment solutions through

vehicles such as Fair Deal Agreements, strengthening and growing customer relationships and enhancing market access.

"The first and third quarters are our seasonally

softest, and three of this year's four largest medical conferences are in the first quarter. These events impact sales as prospective

customers are out of the office, and they also impact expenses as we leverage these important opportunities. Regarding sales, we expect

that first quarter 2025 sales could be considerably lower than first quarter 2024 sales, with full-year sales growth in 2025

versus 2024," he concluded.

Quarter Financial Results

for the fourth quarter of 2024 were $13.1 million, compared with $12.6 million for the fourth quarter of 2023. The increase reflects

a higher number of units sold.

Cost of sales was $6.0 million for the

fourth quarter of 2024, compared with $4.7 million for the prior-year quarter. The increase was primarily related to a higher

number of units sold and higher cost of service.

profit for the fourth quarter of 2024 was $7.1 million, or 54.4% of revenues, compared with $7.8 million, or 62.3% of

revenues, for the fourth quarter of 2023. The decrease was primarily due to a one-time discount to a new large group customer

and higher cost of service.

and administrative expenses were $2.4 million for the fourth quarter of 2024, compared with $0.9 million for the prior-year quarter.

The increase was primarily due to higher compensation and professional fees.

and marketing expenses were $1.4 million for the fourth quarter of 2024, compared with $0.6 million for the prior-year quarter.

The increase was primarily attributable to higher commissions, offset by a decrease in tradeshow cost and marketing expense.

and development expenses were $1.6 million for the fourth quarter of 2024, compared with $0.7 million for the prior-year quarter.

The increase was primarily due to higher compensation expenses and product development cost.

income, net was $0.2 million for the fourth quarter of both 2024 and 2023, and relates primarily to interest income.

income for the fourth quarter of 2024 was $1.5 million, or $0.09 per diluted share, compared with net income of $4.2 million,

or $0.26 per diluted share, for the fourth quarter of 2023.

EBITDA for the fourth quarter of 2024 was $1.9 million, compared with $5.7 million for the fourth quarter of 2023. The decline

reflects higher net income and income tax expense in the 2023 quarter. Adjusted EBITDA, a non-GAAP financial measure, is defined

as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation

between GAAP and non-GAAP financial measures, and the reason these non-GAAP financial measures are provided.

Cash and cash equivalents were $22.1 million

as of December 31, 2024, compared with $23.1 million as of December 31, 2023. The Company had no outstanding borrowings under its

revolving line of credit at either year-end. Prepaid inventory was $3.3 million as of December 31, 2024, compared with $3.0 million

as of December 31, 2023. Inventories were $10.1 million as of December 31, 2024, compared with $11.9 million as of December 31,

Year Financial Results

of $41.8 million in 2024 increased by $17.4 million from $24.4 million in 2023. The increase was primarily driven by a higher

number of units sold to a large customer in 2024.

of sales of $17.4 million in 2024 increased by $7.1 million from $10.3 million in 2023. The increase was primarily related to

a higher number of units sold in 2024.

profit in 2024 of $24.4 million, or 58.4% of revenue, increased by $10.3 million from $14.1 million, or 57.8% of revenue, in 2023.

The increase was primarily driven by a higher number of units sold in 2024.

and administrative expenses of $7.1 million in 2024 increased by $1.9 million from $5.2 million in 2023. The increase was primarily

due to higher compensation, professional fees and bad debt expense, which were offset by a reduction in bank fees and insurance

and marketing expenses of $5.0 million in 2024 decreased by $0.6 million from $5.6 million in 2023. The decrease was primarily

attributable to lower marketing agency expense, travel expense, and payroll costs due to lower headcount.

and development expenses of $4.2 million in 2024 increased by $0.5 million from $3.7 million in 2023. The increase was primarily

due to higher compensation expenses and product development costs, offset by lower expenses related to a project to develop a

drug delivery system for aesthetic use during 2024.

income, net of $0.9 million and $1.0 million in 2024 and 2023, respectively, relates primarily to interest income.

income for 2024 was $6.6 million or $0.41 per diluted share, compared with net income of $0.5 million, or $0.03 per diluted share,

EBITDA for 2024 was $8.7 million, compared with $0.3 million for 2023.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles

generally accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure,

in its analysis of the Company's performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures,

nor should it be viewed as a substitute for operating results determined in accordance with GAAP. Management believes the presentation

of Adjusted EBITDA, which excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense,

provides useful supplemental information that is essential to a proper understanding of the financial results of Sensus Healthcare.

Non-GAAP financial measures are not formally defined by GAAP, and other entities may use calculation methods that differ from

those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes that Adjusted EBITDA assists

investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure

underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided in the

GAAP TO NON-GAAP RECONCILIATION

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management

will discuss these financial results, provide a business update and answer questions.

are encouraged to pre-register for the conference call here to receive a unique dial-in number that will permit them to

bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Alternatively,

participants can access the conference call by dialing 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International).

Please direct the operator to be connected to the Sensus Healthcare conference call. The call will be webcast live and can be

accessed here or in the Investor Relations section of the Company's website at www.sensushealthcare.com.

the conclusion of the conference call, a replay will be available until March 5, 2025 and can be accessed by dialing 877-344-7529

(U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 5636219. An archived webcast

of the call will also be available in the Investors section of the Company's website.

Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging

its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly

effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare

offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

This press release includes statements

that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking

terminology such as "believes," "estimates," "anticipates," "expects," "plans,"

"intends," "may," "could," "might," "will," "should," "approximately,"